In vitro antimalarial activity of tigecycline against Plasmodium falciparum culture-adapted reference strains and clinical isolates from the Brazilian Amazon
AUTOR(ES)
Ribatski-Silva, Daniele, Bassi, Carmen Lucia, Martin, Thamires Oliveira Gasquez, Alves-Junior, Eduardo, Gomes, Luciano Teixeira, Fontes, Cor Jésus Fernandes
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
2014
RESUMO
Introduction: We evaluated the in vitro antimalarial activity of tigecycline as an alternative drug for the treatment of severe malaria. Methods: A chloroquine-sensitive Plasmodium falciparum reference strain, a chloroquine-resistant reference strain, and three clinical isolates were tested for in vitro susceptibility to tigecycline. A histidine-rich protein in vitro assay was used to evaluate antimalarial activity. Results: The geometric-mean 50% effective concentration (EC50%) of tigecycline was 535.5 nM (confidence interval (CI): 344.3-726.8). No significant correlation was found between the EC50% of tigecycline and that of any other tested antimalarial drug. Conclusions: Tigecycline may represent an alternative drug for the treatment of patients with severe malaria.
Documentos Relacionados
- Serotyping of cell culture-adapted subgroup 2 human rotavirus strains by neutralization.
- Reactivities of serotyping monoclonal antibodies with culture-adapted human rotaviruses.
- In Vitro Activity of Lumefantrine (Benflumetol) against Clinical Isolates of Plasmodium falciparum in Yaoundé, Cameroon
- Desbutyl-Benflumetol, a Novel Antimalarial Compound: In Vitro Activity in Fresh Isolates of Plasmodium falciparum from Thailand
- Characterization of C-Type Particles Produced by a Tissue Culture-Adapted Murine Myeloma